References
- Beavo J A, Reifsnyder D H. Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors. Trends in Pharm. Sci. 1990; 11: 150–155
- Heller M. Cardiac glycosides. New/old ideas about old drugs. Biochem. Pharmacol. 1990; 40: 919–925
- Pagani E D, Alousi A A, Grant A M, Older T M, Dziuban S W, Allen P D. Changes in myofibrillar content and MgATPase activity in ventricular tissues from patients with heart failure caused by coronary artery disease, cardiomyopathy, or mitral valve insufficiency. Circ. Res. 1988; 63: 380–385
- Silver P J, Allen P, Etzler J H, Hamel L T, Bentley R G, Pagani E D. Cellular distribution and pharmacological sensitivity of low Km cyclic nucleotide phosphodiesterase isozymes in human cardiac muscle from normal and cardiomyopathic subjects. Second Messengers and Phosphoproteins 1990; 13: 13–25
- Silver P J, Pinto P B, Dachiw J. Modulation of vascular and cardiac contractile protein regulatory mechanisms by calmodulin inhibitors and related compounds. Biochem. Pharmacol. 1986; 35: 2545–2552